WO2026055480A1 - Inhibiteurs de hpdl pour traiter des maladies non malignes - Google Patents

Inhibiteurs de hpdl pour traiter des maladies non malignes

Info

Publication number
WO2026055480A1
WO2026055480A1 PCT/US2025/045128 US2025045128W WO2026055480A1 WO 2026055480 A1 WO2026055480 A1 WO 2026055480A1 US 2025045128 W US2025045128 W US 2025045128W WO 2026055480 A1 WO2026055480 A1 WO 2026055480A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
hydrogen
subject
optionally substituted
phenylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/045128
Other languages
English (en)
Inventor
Michael Pacold
Robert BANH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Publication of WO2026055480A1 publication Critical patent/WO2026055480A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne diverses méthodes de traitement d'une maladie ou d'une affection, telle qu'un cancer, une maladie auto-immune ou toute maladie impliquant une prolifération cellulaire, comprenant l'administration au sujet d'une quantité efficace d'un composé inhibiteur de HPDL ou d'une composition pharmaceutique telle que décrite dans la description.
PCT/US2025/045128 2024-09-06 2025-09-05 Inhibiteurs de hpdl pour traiter des maladies non malignes Pending WO2026055480A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463691917P 2024-09-06 2024-09-06
US63/691,917 2024-09-06

Publications (1)

Publication Number Publication Date
WO2026055480A1 true WO2026055480A1 (fr) 2026-03-12

Family

ID=99014233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/045128 Pending WO2026055480A1 (fr) 2024-09-06 2025-09-05 Inhibiteurs de hpdl pour traiter des maladies non malignes

Country Status (1)

Country Link
WO (1) WO2026055480A1 (fr)

Similar Documents

Publication Publication Date Title
EP2665481B1 (fr) Méthodes et compositions pour le traitement du syndrome métabolique
JP2024037891A (ja) 黒色腫の治療のための組合せ医薬
US20250170082A1 (en) Hpdl inhibitors and uses thereof
US20230364115A1 (en) Novel psychedelic compositions, delivery systems and therapeutic uses thereof
RS58235B1 (sr) Triazin jedinjenje i njegova upotreba u medicinske svrhe
KR20190133245A (ko) 지방세포의 처리
US20250276962A1 (en) Contraceptive compounds and methods
US20210252011A1 (en) Treatment of glioblastoma with fasn inhibitors
CN104011048B (zh) 作为磷酸二酯酶抑制剂的[1,2,4]三唑并吡啶类化合物及其应用
AU2024294612A1 (en) 4-hydroxybenozate esters for treatment of hpdl deficiency and other deficiencies of coq10 headgroup synthesis
WO2026055480A1 (fr) Inhibiteurs de hpdl pour traiter des maladies non malignes
WO1991007178A1 (fr) Derives de la pyrimidone et analogues pour le traitement de l'asthme ou certaines affections de la peau
WO2025137572A1 (fr) Réplétion de la coenzyme q10 à l'aide de 4-hma
WO2023081725A1 (fr) Utilisations de rhodoquinone pour le traitement d'une maladie
CN116650468A (zh) 四氢呋喃型木脂素类化合物的用途
US9133212B1 (en) Inhibitors of hemeprotein-catalyzed lipid peroxidation
EP3893914B1 (fr) Maléate de scy-635 et ses utilisations en médecine
US9545385B2 (en) Inhibitors of hemeprotein-catalyzed lipid peroxidation
JP7702145B2 (ja) ミトコンドリア機能障害改善剤
EP4665317A1 (fr) Compositions comprenant de la kétamine, éventuellement en combinaison avec des n-acyléthanolamines, et leurs utilisations
WO2024239762A1 (fr) Inhibiteur de phosphodiestérase-4, composition pharmaceutique le comprenant et utilisation associée
WO2024171073A1 (fr) Compositions comprenant de la 3,4-méthylènedioxyméthamphétamine, éventuellement en combinaison avec des n-acyléthanolamines, et leurs utilisations
EP4665348A1 (fr) Compositions comprenant de l'ibogaïne, éventuellement en combinaison avec des n-acyléthanolamines, et leurs utilisations
WO2025165727A1 (fr) Procédés et compositions pour activer l'immunité antitumorale et améliorer la fonction immunitaire
JP2025144382A (ja) 化合物、アジュバント組成物および医薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25864286

Country of ref document: EP

Kind code of ref document: A1